Bupropion for control of hot flashes in breast cancer survivors: a prospective, double-blind, randomized, crossover, pilot phase II trial
| Autor: | Auro Del Giglio, Geila Ribeiro Nuñez, Rebecca Melo Zanellato, Hélio Pinczowski, Lívia Tateyama, Fernando Luiz Affonso Fonseca, Fernanda Schindler |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Context (language use) Breast Neoplasms Pilot Projects Placebo law.invention Randomized controlled trial law Internal medicine mental disorders medicine Humans Prospective Studies Survivors Psychiatry Bupropion General Nursing Aged Cross-Over Studies Dose-Response Relationship Drug business.industry Beck Depression Inventory Middle Aged Crossover study humanities Sexual Dysfunction Physiological Anesthesiology and Pain Medicine Sexual dysfunction Treatment Outcome Hot Flashes Smoking cessation Antidepressive Agents Second-Generation Female Neurology (clinical) medicine.symptom business medicine.drug |
| Zdroj: | Journal of pain and symptom management. 45(6) |
| ISSN: | 1873-6513 |
| Popis: | Context Hot flashes (HFs) and sexual dysfunction often affect breast cancer (BC) survivors and compromise their quality of life. Bupropion is an antidepressive medication used for smoking cessation and also has been previously studied for the treatment of sexual dysfunction. Objectives We aimed to evaluate bupropion's efficacy in controlling HFs in BC survivors. Methods This was a randomized, double-blind, crossover, placebo-controlled pilot study that enrolled 55 BC survivors who reported more than seven HFs per week. Subjects were randomized to receive either bupropion 150mg twice daily for four weeks followed by one week of washout and four more weeks of placebo twice daily or vice versa. The primary end point was average daily HF activity (number of HFs and a score combining number and severity) reported while on bupropion or on placebo. Secondary end points were sexual dysfunction, depression, and quality of life evaluated with the Arizona Sexual Experience Scale, Beck Depression Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, respectively. Results Bupropion reduced HFs by 1.26 per day and the HF score by 6.31%, whereas placebo reduced HFs by 2.11 per day ( P >0.05) and the HF score by 30.47% ( P >0.05). There were no statistically significant differences between bupropion and placebo in the Arizona Sexual Experience Scale, Beck Depression Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. At the end of the study, 47% of the patients preferred bupropion, whereas 53% preferred placebo. There were no statistically significant differences in side effects between the study groups. Conclusion Compared with placebo, bupropion did not control HFs in this group of BC survivors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect